GLP-1 Receptor Agonism
Mechanism of action in metabolic regulation — how incretin mimetics control glucose, appetite, and gastric emptying.
On this page
Key takeaways
- GLP-1 receptor agonists mimic the incretin hormone GLP-1, enhancing glucose-dependent insulin secretion while suppressing glucagon.
- They also delay gastric emptying and act centrally to reduce appetite — the mechanism behind their weight management effects.
- Semaglutide and tirzepatide show the strongest Phase III efficacy data for both glycemic control and weight loss.
- Tirzepatide is a dual GIP/GLP-1 agonist, not a pure GLP-1 RA — its additional GIP activity may explain superior weight outcomes.
- Common adverse effects are GI-related (nausea, vomiting) and typically attenuate with dose titration.
Overview
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by intestinal L-cells in response to nutrient ingestion. In healthy physiology, GLP-1 potentiates glucose-dependent insulin secretion, suppresses inappropriate glucagon release, slows gastric emptying, and signals satiety centrally.[1]
Native GLP-1 has a half-life of approximately 2 minutes due to rapid degradation by dipeptidyl peptidase-4 (DPP-4). GLP-1 receptor agonists overcome this limitation through structural modifications that confer resistance to DPP-4 cleavage, albumin binding for extended circulation, or fatty acid acylation.[2]
This class has expanded from a diabetes treatment to encompass weight management, cardiovascular risk reduction, and — in emerging trial data — potential applications in NASH, chronic kidney disease, and neurodegenerative conditions.
Why this mechanism matters
- GLP-1 receptor agonism is the most clinically validated peptide mechanism in current practice. Understanding the pathway helps practitioners evaluate both approved agents and investigational compounds targeting the same receptor family.
Signal pathway
The GLP-1 signaling cascade proceeds through a well-characterized sequence from nutrient stimulus to downstream metabolic effects:
The glucose-dependent nature of GLP-1-mediated insulin secretion is clinically significant: unlike sulfonylureas, GLP-1 RAs carry minimal hypoglycemia risk as monotherapy because the insulin stimulus diminishes as blood glucose normalizes.
Approved agents
The following agents are FDA-approved as of this review. They differ in half-life, administration route, receptor selectivity, and clinical indication profile:
| Agent | Half-life | Route | Frequency | Primary indication |
|---|---|---|---|---|
| Semaglutide (Ozempic) | ~7 days | SC | Weekly | T2DM |
| Semaglutide (Wegovy) | ~7 days | SC | Weekly | Weight management |
| Oral semaglutide (Rybelsus) | ~7 days | Oral | Daily | T2DM |
| Liraglutide (Victoza) | ~13 hrs | SC | Daily | T2DM |
| Liraglutide (Saxenda) | ~13 hrs | SC | Daily | Weight management |
| Tirzepatide (Mounjaro) | ~5 days | SC | Weekly | T2DM |
| Tirzepatide (Zepbound) | ~5 days | SC | Weekly | Weight management |
| Dulaglutide (Trulicity) | ~5 days | SC | Weekly | T2DM |
| Exenatide ER (Bydureon) | ~2.4 hrs* | SC | Weekly | T2DM |
Pharmacokinetics
Understanding the pharmacokinetic differences between agents helps practitioners select appropriately for patient-specific factors:
All approved GLP-1 RAs incorporate structural modifications (amino acid substitutions, fatty acid acylation, or Fc fusion) that prevent DPP-4 from cleaving the active peptide.
Semaglutide and liraglutide achieve extended half-lives through non-covalent albumin binding, which slows renal clearance and maintains therapeutic plasma levels.
Oral semaglutide (Rybelsus) co-formulates with SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) to enhance gastric absorption. Bioavailability is ~1% — effective due to high potency, but requires fasting administration.[6]
Weekly agents (semaglutide, tirzepatide, dulaglutide) reach steady state in 4–5 weeks. Dose titration protocols reflect this timeline.
GLP-1 RAs are not primarily renally cleared, but dose adjustments may be warranted in severe renal impairment for some agents. Check prescribing information per agent.
Clinical notes
Adverse effect profile
The most common adverse effects are gastrointestinal: nausea (15–44%), vomiting, diarrhea, and constipation. These are dose-dependent and typically attenuate over 4–8 weeks with continued use. Slow dose titration is the primary mitigation strategy.
Cardiovascular outcomes
Liraglutide (LEADER trial), semaglutide (SUSTAIN-6, SELECT), and dulaglutide (REWIND) have demonstrated cardiovascular benefit in dedicated outcomes trials. Semaglutide’s SELECT trial showed MACE reduction in non-diabetic patients with obesity, extending the cardiovascular indication beyond T2DM.
Emerging indications
Active Phase II/III programs are evaluating GLP-1 RAs in NASH/MASH (semaglutide), Alzheimer’s disease (liraglutide), obstructive sleep apnea (tirzepatide), and chronic kidney disease progression. These remain investigational as of this review.
Practitioner note
- This explainer covers the mechanism of action, not prescribing protocols. For agent-specific dosing, contraindications, and monitoring parameters, consult the current prescribing information for each agent.
Continue learning
Explore the full metabolic peptide series or find a peptide-competent clinic for patient referral.
Related explainers
References
-
1
"Mechanisms of action and therapeutic application of glucagon-like peptide-1." Cell Metab (2018) doi:10.1016/j.cmet.2018.03.001
-
2
"The discovery and development of liraglutide and semaglutide." Front Endocrinol (2019) doi:10.3389/fendo.2019.00155
-
3
"GLP-1 receptor agonists and cardiovascular events: a systematic review and meta-analysis." Lancet Diabetes Endocrinol (2021) doi:10.1016/S2213-8587(21)00203-5
-
4
"Incretin hormones: their role in health and disease." Diabetes Obes Metab (2018) doi:10.1111/dom.13129
-
5
"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes." N Engl J Med (2021) doi:10.1056/NEJMoa2107519
-
6
"Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist." Sci Transl Med (2018) doi:10.1126/scitranslmed.aar7047
-
7
"Once-weekly semaglutide in adults with overweight or obesity (STEP 1)." N Engl J Med (2021) doi:10.1056/NEJMoa2032183
-
8
"Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT)." N Engl J Med (2023) doi:10.1056/NEJMoa2307563